News from abbvie A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

18:00 ET

AbbVie Announces Top-line Results from Phase 3 Study of All-Oral Treatment for Hepatitis C in Japan

- 95 percent SVR12 rate achieved in Japanese patients new to therapy with genotype 1b chronic hepatitis C virus infection without cirrhosis and...

07:47 ET

AbbVie Reports Fourth-Quarter and Full-Year 2014 Financial Results

 AbbVie (NYSE:ABBV) today announced financial results for the fourth quarter and full year ended Dec. 31, 2014. "AbbVie delivered exceptional...

Jan 16, 2015, 10:08 ET

AbbVie Announces U.S. FDA Approval of DUOPA™ (carbidopa and levodopa) Enteral Suspension for the Treatment of Motor Fluctuations in Patients with Advanced Parkinson's Disease

The U.S. Food and Drug Administration (FDA) has approved AbbVie's (NYSE: ABBV) DUOPA™ (carbidopa and levodopa) enteral suspension for the...

Jan 16, 2015, 07:00 ET

AbbVie to Host Fourth-Quarter and Full-Year 2014 Earnings Conference Call

 AbbVie (NYSE: ABBV) will announce its fourth-quarter and full-year 2014 financial results on Friday, Jan. 30, 2015, before the market...

Jan 16, 2015, 02:00 ET

European Commission Grants Marketing Authorizations for AbbVie's VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) for the Treatment of Chronic Hepatitis C

 AbbVie (NYSE: ABBV) announced that the European Commission has granted marketing authorizations for its all-oral, short-course,...

Jan 12, 2015, 08:00 ET

AbbVie Announces U.S. FDA Approval of DUOPA™ (carbidopa and levodopa) Enteral Suspension for the Treatment of Motor Fluctuations in Patients with Advanced Parkinson's Disease

 The U.S. Food and Drug Administration (FDA) has approved AbbVie's (NYSE: ABBV) DUOPA™ (carbidopa and levodopa) enteral suspension for...

Jan 08, 2015, 16:07 ET

AbbVie Issues Strong Outlook for 2015

 AbbVie (NYSE: ABBV) today issued earnings-per-share guidance for the full-year 2015.  AbbVie expects diluted earnings per share of...

Jan 08, 2015, 08:00 ET

AbbVie Announces Positive Top-Line Results From Phase 3 Study of Investigational Medicine Elagolix in Patients with Endometriosis

 AbbVie (NYSE: ABBV), in cooperation with Neurocrine Biosciences, Inc. (NASDAQ: NBIX), announced positive top-line results from the first of...

Dec 30, 2014, 16:05 ET

AbbVie to Present at 33rd Annual J.P. Morgan Healthcare Conference

AbbVie (NYSE: ABBV) will participate in the 33rd Annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 14, 2015. Bill Chase, executive vice...

Dec 23, 2014, 08:00 ET

AbbVie to Present at Goldman Sachs Healthcare CEOs Unscripted Conference

 AbbVie (NYSE: ABBV) will participate in the Goldman Sachs Healthcare CEOs Unscripted Conference on Tuesday, Jan. 6, 2015. Richard A. Gonzalez,...

Dec 23, 2014, 07:00 ET

AbbVie Receives Health Canada Approval of HOLKIRA™ PAK for the Treatment of Chronic Genotype 1 Hepatitis C

- New all-oral, short-course (12 weeks), interferon-free treatment available in Canada for genotype 1 hepatitis C patients - In Phase 3...

Dec 19, 2014, 17:45 ET

AbbVie Receives U.S. FDA Approval of VIEKIRA PAK™ (Ombitasvir/Paritaprevir/Ritonavir Tablets; Dasabuvir Tablets) for the Treatment of Chronic Genotype 1 Hepatitis C

 The U.S. Food and Drug Administration (FDA) has approved AbbVie's (NYSE:ABBV) VIEKIRA PAK™, an all-oral, interferon-free treatment, with...

Dec 07, 2014, 20:15 ET

AbbVie Presents Results from Phase 2 Study of Investigational Compound Venetoclax (ABT-199/GDC-0199) in Acute Myelogenous Leukemia at the 56th American Society of Hematology Annual Meeting

 AbbVie (NYSE: ABBV) presented during an oral presentation at the American Society of Hematology's 56th Annual Meeting new results from a Phase...

Nov 21, 2014, 08:00 ET

CHMP Grants Positive Opinions of AbbVie's VIEKIRAX™ (ombitasvir/paritaprevir/ritonavir) + EXVIERA™ (dasabuvir) for the Treatment of Chronic Hepatitis C in Europe

 The European Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted positive opinions for...

Nov 17, 2014, 09:00 ET

AbbVie to Present Data on Investigational Oncology Compounds at the 56th American Society of Hematology Annual Meeting

AbbVie (NYSE: ABBV) will present data evaluating three investigational compounds from the company's oncology pipeline at the upcoming 56th American...

Nov 17, 2014, 07:00 ET

AbbVie to Present at Jefferies 2014 Global Healthcare Conference

 AbbVie (NYSE: ABBV) will participate in the Jefferies 2014 Global Healthcare Conference in London on Thursday, Nov. 20, 2014. Bill Chase,...

Nov 14, 2014, 16:48 ET

AbbVie Presents Results from Study of ABT-414 in Patients with Glioblastoma Multiforme at the 19th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology

 AbbVie (NYSE: ABBV) released updated interim results from a Phase 1 clinical trial of ABT-414 in patients with glioblastoma multiforme, an...

Nov 13, 2014, 09:00 ET

AbbVie's Leadership in Immunology Featured at 2014 American College of Rheumatology Annual Meeting with New Data on Investigational Medicines and HUMIRA® (adalimumab)

AbbVie (NYSE: ABBV) announced that data from 37 abstracts related to HUMIRA® (adalimumab), rheumatologic diseases and investigational...

Nov 11, 2014, 09:00 ET

AbbVie to Present Results from Studies in Chronic Hepatitis C Patients with HIV-1 Co-Infection (TURQUOISE-I) and Liver Transplant Recipients (CORAL-I) at The Liver Meeting® 2014

 AbbVie (NYSE: ABBV) today announced results from studies in chronic hepatitis C patients with human immunodeficiency virus type 1 (HIV-1)...

Nov 11, 2014, 08:00 ET

AbbVie to Present Results from Phase 2 PEARL-I Study in Genotype 4 Chronic Hepatitis C Patients at The Liver Meeting® 2014

 AbbVie (NYSE:ABBV) announced detailed results from its open-label Phase 2b study, PEARL-I, which demonstrated that 100 percent  of...